Company news

Candel Therapeutics, Inc. news in 2026

Candel Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

November 6, 2026

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 5, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 2, 2026

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

October 29, 2026

Candel Therapeutics to Present at November Investor Conferences

October 27, 2026

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

October 22, 2026

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

October 2, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

October 1, 2026

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

September 30, 2026

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

September 30, 2026

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

September 10, 2026

Candel Therapeutics to Present at September Investor Conferences

August 26, 2026

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 13, 2026

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

August 3, 2026

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

July 29, 2026

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 8, 2026

July 9, 2026

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 8, 2026

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer

July 1, 2026

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

June 30, 2026

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

June 25, 2026

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

June 1, 2026

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

May 15, 2026

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

May 4, 2026

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

April 29, 2026

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

March 17, 2026

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

March 11, 2026

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

March 9, 2026

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

February 24, 2026

Candel Therapeutics Announces Pricing of Public Offering

February 19, 2026

Candel Therapeutics Announces Proposed $100 Million Public Offering

February 19, 2026

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

February 19, 2026

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

February 11, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2026

Decks in 2026